NGL Fine-Chem Limited
NSE: NGLFINE BSE: NGLFINE
Prev Close
2256.6
Open Price
2260
Volume
3,822
Today Low / High
2260 / 2414.9
52 WK Low / High
980 / 2575
Range
2,245 - 2,482
Prev Close
2249.95
Open Price
2295.1
Volume
527
Today Low / High
2289.65 / 2414.9
52 WK Low / High
985.05 / 2596
Range
2,238 - 2,473
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 2363.6 (target range: 2,245 - 2,482), reflecting a change of 107 (4.74165%). On the BSE, it is listed at 2355.35 (target range: 2,238 - 2,473), showing a change of 105.4 (4.68455%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
NGL Fine-Chem Limited Graph
NGL Fine-Chem Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for NGL Fine-Chem Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 2,363.60, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 2,355.35 | 2,378.90 | 2,141.01 - 2,616.79 |
| 2,402.46 | 1,921.97 - 2,882.95 | ||
| 2,426.01 | 1,698.21 - 3,153.81 | ||
| Bearish Scenario | 2,355.35 | 2,331.80 | 2,098.62 - 2,564.98 |
| 2,308.24 | 1,846.59 - 2,769.89 | ||
| 2,284.69 | 1,599.28 - 2,970.10 |
Overview of NGL Fine-Chem Limited
ISIN
INE887E01022
Industry
Drug Manufacturers - General
Vol.Avg
5,991
Market Cap
14,840,849,253
Last Dividend
1.75
Official Website
IPO Date
2022-07-08
DCF Diff
3,681.92
DCF
-1,412
Financial Ratios Every Investor Needs
Stock Dividend of NGLFINE
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-08-12 | August 12, 25 | 1.75 | 1.75 | 2025-08-12 | 2025-08-26 | |
| 2024-08-16 | August 16, 24 | 1.75 | 1.75 | 2024-08-16 | 2024-09-22 | |
| 2023-08-17 | August 17, 23 | 1.75 | 1.75 | 2023-08-18 | 2023-09-24 | |
| 2022-06-22 | June 22, 22 | 1.75 | 1.75 | 2022-06-23 | 2022-07-30 | |
| 2021-08-12 | August 12, 21 | 1.75 | 1.75 | 2021-08-13 | 2021-09-19 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 368.26 Cr | 182.41 Cr | 185.85 Cr | 0.5047 | 5.02 Cr | 57.05 Cr | 22.43 Cr | 21.12 Cr | 34.19 | 33.87 Cr | 0.0574 |
| 2024-03-31 | 338.69 Cr | 169.08 Cr | 169.61 Cr | 0.5008 | 4.74 Cr | 6.21 Cr | 42.10 Cr | 41.32 Cr | 66.88 | 67.87 Cr | 0.1220 |
| 2023-03-31 | 278.08 Cr | 140.32 Cr | 137.76 Cr | 0.4954 | 2.43 Cr | 38.49 Cr | 23.67 Cr | 20.50 Cr | 33.18 | 40.49 Cr | 0.0737 |
| 2022-03-31 | 317.50 Cr | 146.99 Cr | 165.84 Cr | 0.5223 | 1.74 Cr | 3.84 Cr | 57.83 Cr | 49.90 Cr | 80.77 | 78.88 Cr | 0.1572 |
| 2021-03-31 | 257.97 Cr | 102.34 Cr | 152.66 Cr | 0.5918 | 1.87 Cr | 3.26 Cr | 75.96 Cr | 56.72 Cr | 91.81 | 88.13 Cr | 0.2199 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 5.86 Cr | 433.39 Cr | 150.96 Cr | 282.4346 Cr | 73.15 Cr | 67.29 Cr | 51.27 Cr | 191.85 Cr | 0.00 Cr | 0.00 Cr | 1.00 Cr | 118.9700 Cr |
| 2024-03-31 | 0.40 Cr | 355.54 Cr | 92.90 Cr | 262.6319 Cr | 34.00 Cr | 33.61 Cr | 43.30 Cr | 130.82 Cr | 0.00 Cr | 0.00 Cr | 4.62 Cr | 86.5872 Cr |
| 2023-03-31 | 7.83 Cr | 287.08 Cr | 64.53 Cr | 222.5491 Cr | 32.50 Cr | 22.65 Cr | 26.99 Cr | 113.90 Cr | 5.30 Cr | 2.70 Cr | 4.39 Cr | 58.2917 Cr |
| 2022-03-31 | 0.64 Cr | 276.93 Cr | 73.71 Cr | 203.2179 Cr | 30.00 Cr | 29.36 Cr | 56.01 Cr | 94.75 Cr | 1.93 Cr | 2.55 Cr | 2.57 Cr | 65.6504 Cr |
| 2021-03-31 | 2.10 Cr | 207.77 Cr | 53.31 Cr | 154.4578 Cr | 16.45 Cr | 14.35 Cr | 37.85 Cr | 75.98 Cr | 1.03 Cr | 2.46 Cr | -27.11 Cr | 41.7652 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 35.8221 Cr | -34.5528 Cr | -1.0812 Cr | -94.9494 Cr | 0.1881 Cr | 0.5833 Cr | -130.7715 Cr | 21.1243 Cr | 40.7110 Cr | -1.0812 Cr | -7.9666 Cr |
| 2024-03-31 | 20.4653 Cr | -26.8173 Cr | -1.0812 Cr | -8.0588 Cr | -7.4332 Cr | 0.3952 Cr | -28.5241 Cr | 41.3167 Cr | 1.9637 Cr | -1.0812 Cr | -16.3102 Cr |
| 2023-03-31 | 35.2862 Cr | -27.0204 Cr | -1.0812 Cr | 3.8795 Cr | 7.1846 Cr | 7.8284 Cr | -31.4067 Cr | 27.3620 Cr | 3.6149 Cr | -1.0812 Cr | 29.0143 Cr |
| 2022-03-31 | 13.8246 Cr | -14.2030 Cr | -1.0812 Cr | -42.5518 Cr | -1.4595 Cr | 0.6438 Cr | -56.3764 Cr | 66.5964 Cr | 15.9007 Cr | -1.0812 Cr | -18.1570 Cr |
| 2021-03-31 | 27.3541 Cr | -24.5685 Cr | -1.0812 Cr | 10.1422 Cr | 1.7044 Cr | 2.1033 Cr | -17.2119 Cr | 77.5895 Cr | -11.9626 Cr | -1.0812 Cr | -9.9537 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 127.51 Cr | 81.78 Cr | 45.73 Cr | 0.3587 | 17.13 Cr | 15.69 Cr | 25.40 | 26.93 Cr | 0.1231 |
| 2025-09-30 | 120.26 Cr | 57.27 Cr | 62.99 Cr | 0.5238 | 12.07 Cr | 9.63 Cr | 15.58 | 19.21 Cr | 0.0800 |
| 2025-06-30 | 104.19 Cr | 51.89 Cr | 52.29 Cr | 0.5019 | 6.71 Cr | 9.24 Cr | 14.96 | 17.33 Cr | 0.0887 |
| 2025-03-31 | 94.97 Cr | 47.80 Cr | 47.17 Cr | 0.4967 | 32.92 Cr | 0.54 Cr | 0.88 | 6.11 Cr | 0.0057 |
| 2024-12-31 | 89.10 Cr | 43.53 Cr | 45.57 Cr | 0.5115 | 2.00 Cr | 1.28 Cr | 2.07 | 4.96 Cr | 0.0143 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 1.90 Cr | 61.83 Cr | 63.73 Cr | 112.60 Cr | 67.10 Cr | 266.46 Cr | 205.11 Cr | 484.12 Cr | 183.92 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 65.53 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -282.43 Cr |
| 2025-03-31 | 5.86 Cr | 59.66 Cr | 65.53 Cr | 81.55 Cr | 51.27 Cr | 235.38 Cr | 191.85 Cr | 433.39 Cr | 150.96 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 98.99 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -280.29 Cr |
| 2024-09-30 | 6.00 Cr | 89.59 Cr | 98.99 Cr | 75.28 Cr | 43.46 Cr | 235.28 Cr | 149.37 Cr | 395.85 Cr | 115.56 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 9.24 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 0.54 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 1.28 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 9.81 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 9.22 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - General
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Cipla Limited | CIPLA | ₹1,333.50 | ₹1,077,175,532,780.00 | ₹1,049,578.00 |
| Abbott India Limited | ABBOTINDIA | ₹26,810.00 | ₹569,693,786,620.00 | ₹9,947.00 |
| GlaxoSmithKline Pharmaceuticals Limited | GLAXO | ₹2,487.00 | ₹421,312,806,558.00 | ₹60,117.00 |
| Gland Pharma Limited | GLAND | ₹1,688.20 | ₹278,141,793,309.00 | ₹64,054.00 |
| Pfizer Limited | PFIZER | ₹4,803.50 | ₹219,749,230,662.00 | ₹16,656.00 |
| Sanofi Consumer Healthcare India Ltd. | SANOFICONR | ₹4,536.00 | ₹104,466,901,392.00 | ₹16,725.00 |
| Sanofi India Limited | SANOFI | ₹3,667.10 | ₹84,455,593,936.00 | ₹23,422.00 |
| Marksans Pharma Limited | MARKSANS | ₹174.06 | ₹78,877,681,629.00 | ₹409,913.00 |
| SMS Pharmaceuticals Limited | SMSPHARMA | ₹420.30 | ₹39,361,935,600.00 | ₹1,366,966.00 |
| Senores Pharmaceuticals Ltd. | SENORES | ₹759.70 | ₹34,986,910,804.00 | ₹108,067.00 |
Key Executives
Gender: male
Year Born:
Gender: male
Year Born: 1964
Gender: male
Year Born: 1976
Gender: female
Year Born:
FAQs about NGL Fine-Chem Limited
The CEO is Rahul Jayant Nachane.
The current price is ₹2,402.20.
The range is ₹980-2575.
The market capitalization is ₹1,484.08 crores.
The dividend yield is 0.07%.
The P/E ratio is 42.28.
The company operates in the Healthcare sector.
Overview of NGL Fine-Chem Limited (ISIN: INE887E01022) is a leading Drug Manufacturers - General in India. With a market capitalization of ₹1,484.08 crores and an average daily volume of 5,991 shares, it operates in the Drug Manufacturers - General. The company last declared a dividend of ₹1.75.